NVOS (NVOS) Stock Price & Analysis
NVOS (NVOS) rose 0.00% to USD 0.01 as of June 10, 2026 at 05:29 UTC, according to Nexqual real-time market data.
NVOS last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 1,507 shares. Market capitalization is $177,572, with a 52-week range of USD 0–0.06 (PNK). Source: Nexqual, June 10, 2026 at 05:29 UTC.
Key Statistics (as of June 10, 2026 at 05:29 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0 – 0.06 |
| Volume | 1,507 shares |
| Market Cap | $177,572 |
| Exchange | PNK |
Technical Analysis (NVOS)
Nexqual's technical model rates NVOS "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 05:29 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.56 (neutral) |
| vs SMA50 | Above (USD 0.01) |
| MACD | 0 (positive) |
Analyst Ratings (NVOS)
Wall Street analysts rate NVOS "None", per Nexqual as of June 10, 2026 at 05:29 UTC.
| Consensus Rating | None |
|---|
Earnings (NVOS)
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financials & Fundamentals (NVOS)
| Total Revenue | $13.29M |
|---|---|
| Revenue Growth (YoY) | -6.70% |
| Gross Margin | +43.20% |
| Operating Margin | -30.39% |
| Profit Margin | -121.61% |
| ROE | -82.47% |
| Debt / Equity | 40.92 |
| Current Ratio | 0.37 |
| Total Cash | $844,584 |
| Total Debt | $5.98M |
| Free Cash Flow | $4.82M |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financial Health Score (NVOS)
Nexqual rates NVOS's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:29 UTC.
| Growth | Weak — Revenue -7% YoY (latest Q), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $845K cash vs $6M debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -82%, ROA -15.3% |
Ownership (NVOS)
| Insider Ownership | +6.59% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 19.73M |
| Float | 18.43M |
| Short % of Float | +1.45% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Leadership (NVOS)
NVOS is led by Robert Mattacchione (age 56), Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 05:29 UTC.
| Chairman of the Board & CEO | Robert Mattacchione (age 56) |
|---|---|
| COO & Director | Christopher Mehlin David (age 66) |
Major Backers & Investors (NVOS)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.51% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | USD 12.9 | ▼ 1.53% |
| GNS | Genius Group Limited | USD 0.23 | ▼ 5.37% |
| COSM | Cosmos Health Inc. | USD 0.22 | ▼ 11.16% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| RNAZ | TransCode Therapeutics, Inc. | USD 4.98 | ▼ 11.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:29 UTC. This page is informational and not investment advice.